Key facts
- Lead Biologics’s last known valuation is $20.7M (Jan 2023).
- It has raised $2.1M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Almi Invest, I Love Lund, SmiLe Incubator.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Lead Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lead Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lead Biologics
Developer of cancer drugs for target therapies designed to challenge and revolutionize cancer care. The company's therapies help in the development of antibody treatments, enabling patients to fight cancer, but also improving the quality of life for patients.
- Sector
- Healthcare
- HQ
- Helsingborg, Sweden
- Founded
- 2022
- Employees
- 2
- Website
- leadbiologics.com/
- Ownership
- Privately Held (backing)
Lead Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lead Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lead Biologics in its N-PORT filings yet. We sweep new filings monthly.